Karyopharm Therapeutics Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M |
| Operating income | -$90.7M | -$119.4M | -$129.5M | -$142.2M | -$98.3M |
| Operating expenses | $236.8M | $264.7M | $275.6M | $299.3M | $308.1M |
| Cash from operations | -$75.4M | -$127.5M | -$92.7M | -$149.6M | -$107.1M |
| Capital expenditure | $0 | $142,000 | $0 | $118,000 | $212,000 |
| Free cash flow | -$75.4M | -$127.6M | -$92.7M | -$149.7M | -$107.3M |
| Total assets | $108.4M | $164.4M | $240.4M | $358.2M | $305.3M |
| Total liabilities | $401.3M | $350.4M | $376.6M | $374.8M | $385.0M |
| Total debt | — | — | — | — | $193.2M |
Shares outstanding 22.7M · Free float 65.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.